about
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosisIsolation and phylogenetic characterization of Ebola viruses causing different outbreaks in GabonEmergence of Zaire Ebola Virus Disease in GuineaPoly(I)-Poly(C12U) but Not Ribavirin Prevents Death in a Hamster Model of Nipah Virus InfectionEarly immune responses accompanying human asymptomatic Ebola infectionsExperimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaClinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, GuineaEarly and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.Towards broad protection against Ebolaviruses.Human asymptomatic Ebola infection and strong inflammatory response.Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells.Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues.Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014.Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.Experimental infection of a nonhuman primate with Loa loa induces transient strong immune activation followed by peripheral unresponsiveness of helper T cells.Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever.Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection.Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa.Immune responses and Lassa virus infection.Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus.[Ebola and Marburg hemorrhagic fever viruses: update on filoviruses].Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophagesEvaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea.Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study.New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors.Towards deep insight into Ebola virus disease.Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014.Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response.The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses.NK cells are strongly activated by Lassa and Mopeia virus-infected human macrophages in vitro but do not mediate virus suppression.Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages.[Epidemics of Ebola haemorrhagic fever in Gabon (1994-2002). Epidemiologic aspects and considerations on control measures]Inflammatory responses in Ebola virus-infected patients.Sequence analysis of the GP, NP, VP40 and VP24 genes of Ebola virus isolated from deceased, surviving and asymptomatically infected individuals during the 1996 outbreak in Gabon: comparative studies and phylogenetic characterization.Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.Evidence for Ebola virus superantigen activity.[Viral zoonoses and emergence: research is just starting].Isolation and partial molecular characterisation of a strain of Ebola virus during a recent epidemic of viral haemorrhagic fever in Gabon.
P50
Q21144780-45F206D7-2C56-49E5-8F5D-815478771D0DQ24647845-E07F31F4-E1D2-4E3E-B828-8E2A2B3E36C4Q25197990-76995655-75DE-4913-B5CA-65664AFBA15BQ27473229-E03FBB49-A1DA-42E3-842F-A42EC862E48FQ28344889-15A3BB2E-A23A-4319-B1A7-D99030291E1FQ28550455-C162AE43-0445-4D40-B742-BCCDE2843235Q29247868-6DBDB158-BA14-495B-AB29-EA11D6365FFAQ33383772-D032C44B-CB64-47A3-9506-58E920826901Q33745567-01EFACC0-C13C-4304-A14B-3DCDE6970DECQ33908286-ED6098D8-63E9-446B-9371-D925398E3195Q33976118-409D8609-08FB-4634-9578-4F7B60C95BE5Q34068493-8CFB5BBF-647C-4D9F-9ED0-B1340FCB66D1Q34580917-4B5C988D-99C1-4D2D-AB52-16C7A6F70D83Q35140402-33674373-099F-43EA-921C-00E3D9589C16Q35547137-6829011D-E5CA-41B5-A8A0-E1367D8C3586Q36288297-9266D33D-15A9-4662-BCDA-BCB2ECE7DB91Q37464889-3FE964DE-B820-417A-89A9-5C1D57C8252FQ37511565-BC30DA6B-C5B1-43CF-8422-7B786911E993Q37896703-316DF448-BF5C-4EFE-B315-B85AB854F21AQ38064284-DF0EC4B9-8640-4513-81B4-98AA08A5B34FQ38349661-46514B11-10A5-4DCD-836D-C29FEE989A0BQ38463251-9FD9183D-D2E6-460E-A167-05ADC936BAD0Q38959283-015103B6-26CD-444C-B12A-AA099B9310CAQ39550507-E86B5804-8C70-45A1-B055-8965DB483EAEQ40064350-8D217855-475F-4B2D-8DAE-25051CD0BBD1Q40072885-DF04E239-49BC-43C0-A14B-EF61F22BCD16Q40082897-B777CF34-A8DC-4F8B-A6EF-549CB8A8A630Q40146185-2C658366-5E2D-4A5D-B18B-076D5BB1BBE1Q40168964-7548D631-4C3C-419C-BF92-240A2D76EE92Q40189585-3C8C930C-1D1B-4AB3-876B-7FF76583D087Q40189592-0D99AC5B-9EF8-4ED1-97E2-F5EDE866DEEFQ40287006-D075DF56-ED56-4787-BFD6-3F811566A082Q40481084-0130003F-E699-4049-956B-D4233EC9566BQ40524559-60DEF444-1E5E-47AC-A28E-AEA8E8DBF64FQ40583360-518C7656-DA5D-408F-9D6D-2EF1011BF96EQ40591728-D0FF32E9-816E-4C43-9F54-23B20DF8E47DQ41928655-ECB0C481-E982-4086-B8AA-3BBD94AB1759Q42779532-EC623505-3F7C-4E22-BA32-507F60F33058Q43568818-F8BE5B77-1069-43D5-B497-CD4C449DDAF9Q44089434-F5AD2298-F445-4906-B497-0CEA2B660023
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Sylvain Baize
@ast
Sylvain Baize
@en
Sylvain Baize
@es
Sylvain Baize
@nl
type
label
Sylvain Baize
@ast
Sylvain Baize
@en
Sylvain Baize
@es
Sylvain Baize
@nl
prefLabel
Sylvain Baize
@ast
Sylvain Baize
@en
Sylvain Baize
@es
Sylvain Baize
@nl
P214
P106
P21
P214
P31
P496
0000-0002-3234-7477
P735
P7859
viaf-203331463